SEC Form 4 · accession 0001209191-17-044902
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Levy
Officer — Chief Medical Officer
Period of report
Jul 11, 2017
Accepted (ET)
Jul 12, 2017 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.63 | Jul 11, 2017 | A | 95,000 | A | — | Jul 11, 2017 | Common Stock | 95,000 | 95,000 | D |
Explanation of responses
- F1The Option vests monthly over a period of four years commencing June 15, 2017.